Helical

Pharmaceutical research is one of the most computationally hungry fields on the planet. Understanding how molecules behave, how they interact with biological targets, how they can be modified to increase efficacy and reduce toxicity — all of this requires processing data at enormous scale. Helical, a London-based startup at the intersection of healthtech and artificial intelligence, has positioned itself as a virtual AI laboratory dedicated to bionuclear pharmaceutical research, bringing the power of deep learning to the processes of drug discovery and development. The concept of a virtual AI lab is central to Helical's proposition: rather than supporting researchers as an analysis tool, the platform is designed as an autonomous research environment, capable of processing hypotheses, analyzing molecular structures, and identifying promising candidates with a speed and depth inaccessible to traditional laboratories. The specific application to bionuclear research — a field studying the interaction between biological molecules and nuclear systems — places Helical in a domain of high technical complexity and significant therapeutic potential. The business model targets the pharmaceutical and biotech industry, where pressure to reduce the time and cost of drug development is constant and where the ability to more rapidly identify candidates with higher probability of clinical success has enormous economic value. Helical can operate both as an AI infrastructure provider for client laboratories and as a research partner in drug discovery programs. The market for AI applied to pharmaceuticals is one of the most dynamic in the entire European deep tech landscape, with growing investment and structural demand from industry. Helical positions itself in this market with a vertical specialization that allows it to offer deep expertise in a specific domain, building a defensible advantage over generalist players.